On March 15, 2023, Johnson & Johnson announced that it has received a shareholder proposal from Oxfam America Inc, requesting the Company to report to shareholders, on whether and how Company subsidiary Janssen's receipt of government financial support for development and manufacture of vaccines and therapeutics for COVID-19 is being, or will be, taken into account when engaging in conduct that affects access to such products, such as setting prices. In addition, the Company recommended the shareholders to vote against the proposal at the annual meeting of shareholders scheduled to be held on April 27, 2023.